|
| Thursday, January 11, 2024 |
|
|
富士通、小売業界で世界最大規模の展示会「NRF 2024」に出展 |
| more info >> |
|
|
Fujitsu highlights unified and sustainable shopper journeys at retail's big show, NRF 2024 |
| Fujitsu will showcase its efforts to build unified and sustainable shopper journeys for retailers at NRF24, "Retail's Big Show" - Jacob K. Javits Convention Center, New York City, January 14-16, 2024, booth #5203. more info >> |
|
| Wednesday, January 10, 2024 |
|
|
Fujitsu prepares for disclosure in line with TNFD framework, registers as TNFD Adopter |
| Fujitsu today announced that in December 2023 it registered as a TNFD Adopter with the aim to start disclosures aligned with the recommendations of the Task Force on Nature-related Financial Disclosures (TNFD) in its corporate reporting. more info >> |
|
|
富士通、TNFDフレームワークに沿った情報開示を宣言 |
| more info >> |
|
| Tuesday, December 26, 2023 |
|
|
Fujitsu to launch dedicated company for hardware business in Japan |
Earlier this year Fujitsu announced its vision for 2030 under a new Mid-term Management Plan, underlining its ambition to transform into "a technology company that realizes net positive outcomes for its stakeholders including society, customers, shareholders and employees, while providing digital services which contribute to sustainability across industries."
more info >> |
|
| Monday, May 22, 2023 |
|
|
Tokyo Tech, Tohoku University, Fujitsu, and RIKEN start collaboration to develop distributed training of Large Language Models |
| Tokyo Institute of Technology (Tokyo Tech), Tohoku University, Fujitsu Limited, and RIKEN today announced that they will embark on the research and development of a distributed training of Large Language Models (LLM) on supercomputer Fugaku in May 2023, within the scope of the initiatives for use of Fugaku defined by Japanese policy. more info >> |
|
| Thursday, May 18, 2023 |
|
Fujitsu launches Biodrug Design Accelerator platform to accelerate peptide drug discovery research
|
| Fujitsu today announced the commercial debut of its "Biodrug Design Accelerator," a platform to manage research processes for peptide drug discovery, which many regard as a promising frontier in the field of new drug development. more info >> |
|
|
富士通、ペプチド創薬の研究プロセスを管理するプラットフォーム「Biodrug Design Accelerator」を提供開始 |
| 当社は、サステナブルな世界の実現を目指す「Fujitsu Uvance」のもと、あらゆる人のライフエクスペリエンスを最大化する「Healthy Living」の取り組みを進めており、次世代の創薬モダリティ（注1）として注目されている中分子創薬領域において、ペプチド（注2）創薬の研究プロセスを管理するプラットフォーム「Biodrug Design Accelerator（バイオドラッグデザインアクセラレーター）」を開発し、2023年5月18日より製薬企業向けに日本国内で提供を開始します。2023年度第3四半期よりグローバルにも順次展開予定です。 more info >> |
|
| Wednesday, May 17, 2023 |
|
|
京都大学・Chordia Therapeutics・富士通、因果関係を発見するAI技術を用いてがんの新薬に対するバイオマーカーを発見する実証実験を開始 |
| 国立大学法人京都大学（注1）（以下、京都大学）、Chordia Therapeutics株式会社（注2）（以下、Chordia社）、富士通株式会社（注3）（以下、富士通）は、データから新たな発見の手がかりを提示する富士通のAIである因果発見技術を用いて、がんの新薬開発における臨床試験の成功確率向上や期間短縮につながるバイオマーカー（注4）を発見するための実証実験を2023年5月17日より開始します。 more info >> |
|
|
Fujitsu, Kyoto University, and Chordia Therapeutics launch AI trials to discover biomarkers for new cancer drugs |
| Fujitsu Limited, Kyoto University, Chordia Therapeutics, Inc., today announced the beginning of field trials leveraging Fujitsu's AI causal discovery technology to shed light on biomarkers that increase the probability of success or shorten the duration of clinical trials in the development of new cancer drugs. more info >> |
|
|
|
|
